<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869622</url>
  </required_header>
  <id_info>
    <org_study_id>VABHS IRB#1889</org_study_id>
    <nct_id>NCT00869622</nct_id>
  </id_info>
  <brief_title>Antiepileptic Drugs and Osteoporotic Prevention Trial</brief_title>
  <acronym>ADOPT</acronym>
  <official_title>Antiepileptic Drugs and Osteoporotic Prevention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston VA Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alliance for Better Bone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Boston Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston VA Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: (e.g., Controlled, Double-Blind, Randomized, Parallel):

      Randomized, double-blind, placebo controlled of a bisphosphonate in the prevention of bone
      loss associated with the use of antiepileptic drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned to last two years. You will be required to make a total of 6 visits to
      the clinic during this two year study period. At the first visit, 12 months and,
      approximately 24 months, you will have a bone mineral density test (BMD) of your hip and
      spine. A BMD is similar to having an x-ray and is a test that measures the amount of bone.
      This test takes approximately 15 minutes. Radiation exposure during this test is very low. It
      has been estimated that the total radiation exposure from a bone mineral density measurement
      is lower than that of a dental x-ray. At each follow up visit an assessment will be made for
      side effects and whether or not you followed the prescribed treatment.

      Initially, information collected will include height, weight, seizure history and seizure
      medication history, other medical conditions, bone and muscle symptoms you currently have,
      dietary calcium intake, and exercise. Blood will be drawn at the initial and 5 follow-up
      visits. The purpose of this is to test your blood for organ function, calcium levels, vitamin
      D levels and levels of markers that show high bone turnover. Also at each visit your height
      and weight will be checked and you will be asked questions regarding side effects, adherence
      to treatment and quality of life.

      When you agree to participate, you will be randomized to either risedronate 35mg tablet
      (Actonel ®) or placebo (a fake pill) to take once a week. Randomization is a process in which
      you will have an equal chance (like the flip of a coin) to be assigned to either risedronate
      (Actonel ®) or placebo. A computer program will determine your treatment assignment. Also
      during the study you will be provided with calcium and vitamin D tablets to take either two
      or three times each day depending on your dietary calcium intake.

      At the first visit you will be assessed for changeable risk factors for osteoporosis. These
      include smoking, alcohol consumption, and lack of physical activity, poor nutrition and lack
      of vitamin intake. Also, blood will be drawn to see if you have a low male hormone. If you
      are found to have low male hormone, you will be referred to your primary care provider. If
      you have low male hormone levels, you will be eligible to participate in the study if
      testosterone replacement has been offered to you and you have declined treatment. If you
      decide to be treated with testosterone you are not eligible to participate in this study.
      Education will be provided on exercises for bones. If you smoke, you will be counseled on
      quitting although quitting is not a requirement to participate in the study. If you drink a
      lot of alcohol you will be counseled on reducing your intake and offered help. Reducing or
      quitting alcohol is not a requirement for your participation in this study. You can also meet
      with a registered dietician for nutritional counseling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Bone Mineral Density</measure>
    <time_frame>2 years</time_frame>
    <description>Patients with a T-Score of &gt; -2.5 were randomized into two possible arms. A bisphosphonate group received 35mg risedronate weekly while another group received an identical placebo tablet weekly. Both groups received supplemental calcium and vitamin D.
Enrolled patients had bone density measurements of bilateral proximal femur, A-P lumbar spine, total body, forearm and L-P spine. All measurements were performed on a GE Lunar Bone Densitometer (iDXA) instrument. Measurements of 25-hydroxy vitamin D, NTX , serum calcium and blood chemistries occurred at scheduled intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vertebral Fractures</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Epilepsy</condition>
  <condition>Bone Loss</condition>
  <condition>Osteoporosis</condition>
  <condition>Fractures</condition>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Calcium and Vitamin D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients both on placebo and active bisphosphonate to receive calcium and vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>35 mgs/week + calcium and vit d</description>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>Actonel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Calcium and Vitamin D</intervention_name>
    <description>sugar pill + calcium 1200mgs/day and vitamin d at least 800IU</description>
    <arm_group_label>Placebo + Calcium and Vitamin D</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male gender

          -  Epilepsy

          -  Anti-epileptic drug treatment with phenytoin, or phenobarbital or valproate sodium

          -  Normal renal function and normal Vitamin D and calcium levels

        Exclusion Criteria:

          -  Female gender

          -  Organ transplant

          -  Use of oral glucocorticoids

          -  Renal insufficiency (eGFR &lt; 30ml/min)

          -  Severe swallowing disorder

          -  Severe esophagitis

          -  Patients taking sodium valproate for reasons other than epilepsy

          -  Previous treatment with osteoporosis drugs such as bisphosphonates, calcitonin or PTH
             analog
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio A Lazzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Boston HCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phillip Dussault, Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Boston HCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manisha Thakore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Boston HCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Boston Healthcare System</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <results_first_submitted>January 28, 2015</results_first_submitted>
  <results_first_submitted_qc>July 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2015</results_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston VA Research Institute, Inc.</investigator_affiliation>
    <investigator_full_name>Antonio Lazzari</investigator_full_name>
    <investigator_title>Director Osteoporosis Prevention and Treatment Center VABHCS</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>fracture</keyword>
  <keyword>antiepileptic drug</keyword>
  <keyword>seizure</keyword>
  <keyword>Prevention of bone loss</keyword>
  <keyword>Prevention of osteoporosis</keyword>
  <keyword>Prevention of Fractures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>80 veterans with epilepsy who were treated with phenobarbital, phenytoin, carbamazepine and sodium valproate.</recruitment_details>
      <pre_assignment_details>80 epileptic patients who have been on phenytoin, phenobarbital, carbamazepine or sodium divalproex for at least 2 years were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Risedronate</title>
          <description>Active drug
Risedronate: 35 mgs/week + calcium and vit d</description>
        </group>
        <group group_id="P2">
          <title>Placebo Sugar Pill</title>
          <description>All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
Placebo + calcium and vitamin d: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risedronate</title>
          <description>Active drug participants received calcium and vitamin D supplementation in addition to 35 mgs of risedronate tablet weekly</description>
        </group>
        <group group_id="B2">
          <title>Placebo Sugar Pill</title>
          <description>Placebo participants received calcium and vitamin D supplementation in addition to a placebo tablet identical to risedronate tablet weekly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="13"/>
                    <measurement group_id="B2" value="58" spread="13"/>
                    <measurement group_id="B3" value="61" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of seizures</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grand Mal Seizures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other types of seizures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smokers</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non Smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Vitamin D Level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="19"/>
                    <measurement group_id="B2" value="29.3" spread="16"/>
                    <measurement group_id="B3" value="29.2" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Vertebral Fractures</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Previous vertebral fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No veterbral fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Bone Mineral Density</title>
        <description>Patients with a T-Score of &gt; -2.5 were randomized into two possible arms. A bisphosphonate group received 35mg risedronate weekly while another group received an identical placebo tablet weekly. Both groups received supplemental calcium and vitamin D.
Enrolled patients had bone density measurements of bilateral proximal femur, A-P lumbar spine, total body, forearm and L-P spine. All measurements were performed on a GE Lunar Bone Densitometer (iDXA) instrument. Measurements of 25-hydroxy vitamin D, NTX , serum calcium and blood chemistries occurred at scheduled intervals.</description>
        <time_frame>2 years</time_frame>
        <population>The study design involved 80 veterans with epilepsy who were treated with phenobarbital, phenytoin, carbamazepine and sodium valproate. This is a prospective study in which 80 patients who have been on phenytoin, phenobarbital, carbamazepine or sodium divalproex for at least 2 years were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>Active drug
Risedronate: 35 mgs/week + calcium and vit d</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sugar Pill</title>
            <description>All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
Placebo + calcium and vitamin d: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bone Mineral Density</title>
          <description>Patients with a T-Score of &gt; -2.5 were randomized into two possible arms. A bisphosphonate group received 35mg risedronate weekly while another group received an identical placebo tablet weekly. Both groups received supplemental calcium and vitamin D.
Enrolled patients had bone density measurements of bilateral proximal femur, A-P lumbar spine, total body, forearm and L-P spine. All measurements were performed on a GE Lunar Bone Densitometer (iDXA) instrument. Measurements of 25-hydroxy vitamin D, NTX , serum calcium and blood chemistries occurred at scheduled intervals.</description>
          <population>The study design involved 80 veterans with epilepsy who were treated with phenobarbital, phenytoin, carbamazepine and sodium valproate. This is a prospective study in which 80 patients who have been on phenytoin, phenobarbital, carbamazepine or sodium divalproex for at least 2 years were enrolled.</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilateral Proximal Femora</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" spread="0.111"/>
                    <measurement group_id="O2" value="0.999" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L1-L4 AP Spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.332" spread="0.111"/>
                    <measurement group_id="O2" value="1.245" spread="0.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Body BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.205" spread="0.096"/>
                    <measurement group_id="O2" value="1.192" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vertebral Fractures</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risedronate</title>
            <description>Active drug
Risedronate: 35 mgs/week + calcium and vit d</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Calcium and Vitamin D</title>
            <description>All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
Placebo + Calcium and Vitamin D: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU</description>
          </group>
        </group_list>
        <measure>
          <title>Vertebral Fractures</title>
          <units>Vertebral Fractures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0229</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Risedronate</title>
          <description>Active drug
Risedronate: 35 mgs/week + calcium and vit d</description>
        </group>
        <group group_id="E2">
          <title>Placebo Sugar Pill</title>
          <description>All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
Placebo + calcium and vitamin d: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio A. Lazzari, M.D., Ph.D</name_or_title>
      <organization>VA Boston Healthcare System</organization>
      <phone>(857) 364-6381</phone>
      <email>Antonio.Lazzari@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

